Acute tumour lysis syndrome: a case in AL amyloidosis

被引：4

作者：

Akasheh, MS ^{[1
]}

Chang, CP ^{[1
]}

Vesole, DH ^{[1
]}

机构：

[1] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Bone Marrow Transplant Unit, Milwaukee, WI 53226 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1999年 / 107卷 / 02期

关键词：

tumour lysis syndrome; ASCT; amyloidosis; multiple myeloma; melphalan;

D O I：

10.1046/j.1365-2141.1999.01719.x

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Tumour lysis syndrome (TLS) in plasma cell dyscrasias is extremely rare. TLS has been described in eight cases of multiple myeloma undergoing high-dose therapy with autologous stem cell transplant (ASCT). Recently, clinical trials of intensive chemotherapy followed by autologous or allogeneic stem cell support has been shown to offer potential benefit in AL (amyloid light-chain) amyloidosis, TLS in primary AL amyloidosis in this setting has not been previously reported. We report a case of TLS in a patient with AL amyloidosis which developed after high-dose melphalan chemotherapy supported by ASCT.

引用

页码：386 / 387

页数：2

共 10 条

[1]

BURTON DR, 1988, MANUAL CLIN PROBLEMS, P304

[2]

Comenzo RL, 1998, BLOOD, V91, P3662

[3]

Fassas A., 1997, Blood, V90, p527A

[4]

KYLE RA, 1975, MEDICINE, V54, P271

[5]

A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine [J].

Kyle, RA ;

Gertz, MA ;

Greipp, PR ;

Witzig, TE ;

Lust, JA ;

Lacy, MQ ;

Therneau, TM .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (17) :1202-1207

[6]

KYLE RA, 1986, BLOOD, V68, P220

[7]

MERLINI G, 1995, SEMIN HEMATOL, V32, P60

[8]

Moreno-Torres C, 1998, BONE MARROW TRANSPL, V21, pS29

[9]

Nakhoul F, 1996, EUR J HAEMATOL, V56, P254

[10]

CLINICAL REMISSION AFTER SYNGENEIC BONE-MARROW TRANSPLANTATION IN A PATIENT WITH AL AMYLOIDOSIS [J].

VANBUREN, M ;

HENE, RJ ;

VERDONCK, LF ;

VERZIJLBERGEN, FJ ;

LOKHORST, HM .

ANNALS OF INTERNAL MEDICINE, 1995, 122 (07) :508-510

← 1 →